🔬 Endocrinology Updates You Shouldn’t Miss: Hormonal Health, Diabetes Risk & More 🧬
From FDA approvals to innovative lifestyle interventions, this week’s endocrinology update covers major developments transforming patient care and research! Whether it’s advancements in treating Cushing’s syndrome, the metabolic impact of subclinical hypothyroidism, or the genetic links in PCOS, we break down what it all means for clinicians, researchers, and patients alike.
📌 In This Episode:
✔️ FDA expands ISTURISA® (osilodrostat) for Cushing’s syndrome — now reaching patients beyond Cushing’s disease
✔️ Digital coaching reduces diabetes risk by more than forty-five percent in prediabetics — without medications
✔️ Beta-hydroxybutyrate shows potential in lowering type 2 diabetes risk, especially in women with impaired fasting glucose
✔️BRCA1 mutations linked to PCOS in South Indian women — shedding light on a potential cancer-PCOS connection
✔️ Subclinical hypothyroidism worsens PCOS metabolic profile — underlining the importance of thyroid screening
✔️Novartis pulls Phase II trial for OA drug QUC398 due to limited pain relief, despite a solid safety profile
📢 Stay Ahead in Endocrinology & Metabolic Research!
✅ Like, share, and subscribe for weekly updates on diabetes, metabolic health, and endocrinology breakthroughs.
#Endocrinology #CushingsSyndrome #DiabetesPrevention #PCOS #ThyroidHealth #HormoneHealth #MedicalResearch #ClinicalTrials #HealthcareInnovation #LQVentures